儿童分化型甲状腺癌远处转移的临床病程与突变图谱
该回顾性研究纳入1946至2019年确诊年龄≤18岁的儿童分化型甲状腺癌远处转移患者148例,其中97%为乳头状癌。中位随访显示93%患者持续带病生存,疾病特异性死亡仅5%且多发生在确诊后数十年。乳头状癌中融合基因高发(RET融合59%、NTRK1/3融合28%),均对应可用靶向治疗。
要点
- 儿童DTC远处转移患者经多程RAI后93%仍持续带病,但疾病特异性死亡仅5%。
- 乳头状癌驱动基因以RET融合(59%)和NTRK1/3融合(28%)为主,BRAF V600E仅13%。
- 已识别的分子改变均有对应靶向药物,未来应减少依赖重复RAI。
核心结论
- 儿童DTC伴远处转移者虽经多程RAI多数持续带病,但疾病特异性死亡不常见且多发生在确诊后数十年。
- 乳头状癌中融合基因高度流行,所有识别的分子改变均有相应靶向治疗可用。
研究设计与样本
- 三级癌症中心回顾性研究,纳入1946至2019年确诊年龄≤18岁的儿童DTC伴远处转移患者148例。
- 144例(97%)为乳头状甲状腺癌,104例(70%)为女性,确诊中位年龄13.4岁(IQR 9.9-15.9岁)。
主要发现
- 可评估患者接受中位2程(IQR 1-3)RAI治疗,中位累积给药活度238.0 mCi(IQR 147.5-351.0 mCi)。
- 69例乳头状癌样本中64例确定致癌驱动:RET融合38/64(59%)、NTRK1/3融合18/64(28%)、BRAF V600E突变8/64(13%)。
- 末次评估时93%患者持续带病;DTC确诊后中位总生存50.7年、疾病特异性生存52.8年。
- 8例(5%)乳头状癌患者死于疾病,死亡距确诊中位30.7年(IQR 20.6-37.6年)。
临床怎么用
- 儿童DTC远处转移患者应认识到长期带病生存常见,疾病特异性死亡少见且多延迟数十年。
- 对乳头状癌可考虑分子检测识别RET或NTRK融合等可靶向改变,为靶向治疗提供依据。
- 未来治疗范式应探索整合分子靶向治疗并减少对重复RAI疗程的依赖。
局限性
- 为单中心回顾性研究,时间跨度1946至2019年,诊疗模式随时间变化可能影响结果。
- 分子检测仅在69例乳头状癌样本中的64例确定驱动基因,并非全部患者可评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Distant metastases (DM) from childhood differentiated thyroid carcinoma (DTC) are uncommon and published studies are limited. OBJECTIVE: This work aimed to describe the outcomes of patients with DM from childhood DTC and to evaluate the molecular landscape of these tumors. METHODS: A retrospective study was conducted at a tertiary cancer center including patients with pediatric DTC (diagnosed at age ≤ 18 years from 1946 to 2019) and DM. RESULTS: We identified 148 patients; 144 (97%) had papillary thyroid carcinoma (PTC) and 104 (70%) were female. Median age at DTC diagnosis was 13.4 years (interquartile range [IQR], 9.9-15.9 years). Evaluable individuals received a median of 2 (IQR, 1-3) radioactive iodine (RAI) treatments at a median cumulative administered activity of 238.0 mCi (IQR, 147.5-351.0 mCi). The oncogenic driver was determined in 64 of 69 PTC samples: RET fusion (38/64; 59%), NTRK1/3 fusions (18/64; 28%), and the BRAF V600E mutation (8/64; 13%). At last evaluation, 93% had persistent disease. The median overall and disease-specific survival after DTC diagnosis were 50.7 and 52.8 years, respectively. Eight (5%) PTC patients died of disease after a median of 30.7 years (IQR, 20.6-37.6 years). CONCLUSION: Childhood DTC with DM persists in most patients despite multiple courses of RAI, but disease-specific death is uncommon, typically occurring decades after diagnosis. Fusion genes are highly prevalent in PTC, and all identified molecular alterations have appropriate targeted therapies. Future studies should focus on expanding genotype-phenotype correlations, determining how to integrate molecularly targeted therapy into treatment paradigms, and relying less on repeated courses of RAI to achieve cure in patients with DM from childhood DTC.
引用
- Nies M, Vassilopoulou-Sellin R, Bassett RL, et al. Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational Landscape. J Clin Endocrinol Metab. 2021. PMID: 33382403. doi:10.1210/clinem/dgaa935
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。